BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31157422)

  • 1. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.
    Vilar-Gomez E; Vuppalanchi R; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Hepatology; 2020 Feb; 71(2):495-509. PubMed ID: 30506586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
    Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
    Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
    JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin does not improve survival in patients with hepatocellular carcinoma.
    Bhat M; Chaiteerakij R; Harmsen WS; Schleck CD; Yang JD; Giama NH; Therneau TM; Gores GJ; Roberts LR
    World J Gastroenterol; 2014 Nov; 20(42):15750-5. PubMed ID: 25400459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.
    Zarrinpar A; Faltermeier CM; Agopian VG; Naini BV; Harlander-Locke MP; Kaldas FM; Farmer DG; Busuttil RW
    Liver Int; 2019 Mar; 39(3):531-539. PubMed ID: 30427105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.
    Nkontchou G; Cosson E; Aout M; Mahmoudi A; Bourcier V; Charif I; Ganne-Carrie N; Grando-Lemaire V; Vicaut E; Trinchet JC; Beaugrand M
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2601-8. PubMed ID: 21752887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
    Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
    Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection.
    Chan KM; Kuo CF; Hsu JT; Chiou MJ; Wang YC; Wu TH; Lee CF; Wu TJ; Chou HS; Lee WC
    Liver Int; 2017 Mar; 37(3):434-441. PubMed ID: 27775209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
    Kaplan DE; Serper M; John BV; Tessiatore KM; Lerer R; Mehta R; Fox R; Aytaman A; Baytarian M; Hunt K; Albrecht J; Taddei TH;
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2148-2160.e14. PubMed ID: 32798709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
    Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
    J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
    Piazza NA; Singal AK
    Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation.
    Chen TM; Lin CC; Huang PT; Wen CF
    J Gastroenterol Hepatol; 2011 May; 26(5):858-65. PubMed ID: 21251068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.
    Akuta N; Kawamura Y; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    BMC Gastroenterol; 2018 Nov; 18(1):165. PubMed ID: 30400829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
    Perazzo H; Munteanu M; Ngo Y; Lebray P; Seurat N; Rutka F; Couteau M; Jacqueminet S; Giral P; Monneret D; Imbert-Bismut F; Ratziu V; Hartemann-Huertier A; Housset C; Poynard T;
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1081-93. PubMed ID: 25186086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis.
    Young S; Sanghvi T; Rubin N; Hall D; Roller L; Charaf Y; Golzarian J
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):65-75. PubMed ID: 31686136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.